Intuitive Surgical (NASDAQ:ISRG) and Cadre (NYSE:CDRE) Head to Head Contrast

Cadre (NYSE:CDRE) and Intuitive Surgical (NASDAQ:ISRG) are both industrial products companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, valuation, dividends, institutional ownership, earnings, risk and analyst recommendations.

Institutional & Insider Ownership

44.0% of Cadre shares are owned by institutional investors. Comparatively, 83.6% of Intuitive Surgical shares are owned by institutional investors. 37.0% of Cadre shares are owned by insiders. Comparatively, 0.8% of Intuitive Surgical shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Volatility and Risk

Cadre has a beta of 1.24, suggesting that its share price is 24% more volatile than the S&P 500. Comparatively, Intuitive Surgical has a beta of 1.39, suggesting that its share price is 39% more volatile than the S&P 500.

Profitability

This table compares Cadre and Intuitive Surgical’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Cadre	6.34%	12.88%	6.06%
Intuitive Surgical	28.51%	13.41%	11.83%

Earnings & Valuation

This table compares Cadre and Intuitive Surgical”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cadre	$482.53 million	3.22	$38.64 million	$0.83	46.06
Intuitive Surgical	$7.12 billion	29.63	$1.80 billion	$6.22	95.28

Intuitive Surgical has higher revenue and earnings than Cadre. Cadre is trading at a lower price-to-earnings ratio than Intuitive Surgical, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current recommendations and price targets for Cadre and Intuitive Surgical, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cadre	0	2	3	0	2.60
Intuitive Surgical	1	3	15	0	2.74

Cadre presently has a consensus target price of $39.75, suggesting a potential upside of 3.99%. Intuitive Surgical has a consensus target price of $554.17, suggesting a potential downside of 6.49%. Given Cadre’s higher probable upside, analysts plainly believe Cadre is more favorable than Intuitive Surgical.

Summary

Intuitive Surgical beats Cadre on 12 of the 14 factors compared between the two stocks.

About Cadre

Cadre Holdings, Inc. manufactures and distributes safety that provides protection to users in hazardous or life-threatening situations in the United States and internationally. The company operates in two segments, Products and Distribution. It offers body armor product, such as concealable, corrections, and tactical armor under the Safariland and Protech Tactical brand names; survival suits, remotely operated vehicles, specialty tools, blast sensors, accessories, and vehicle blast attenuation seats for bomb safety technicians; bomb suits; duty gear, including belts and accessories; and other protective equipment comprising communications gear, forensic and investigation products, firearms cleaning solutions, and crowd control products. The company also offers third-party products, such as uniforms, optics, boots, firearms, and ammunition. It serves first responders, such as state and local law enforcement, fire and rescue, explosive ordnance disposal technicians, emergency medical technicians, fishing, and wildlife enforcement and departments of corrections, as well as federal agencies including the U.S. Department of State, U.S. Department of Defense, U.S. Department of Interior, U.S. Department of Justice, U.S. Department of Homeland Security, U.S. Department of Corrections, the Department of Energy, Los Alamos National Laboratories, Waste Isolation Plant, and various foreign government agencies. Cadre Holdings, Inc. was founded in 1964 and is headquartered in Jacksonville, Florida.

About Intuitive Surgical

Intuitive Surgical, Inc. develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung. It also provides a suite of stapling, energy, and core instrumentation for its multi-port da Vinci surgical systems; progressive learning pathways to support the use of its technology; infrastructure of service and support specialists, a complement of services to its customers, including installation, repair, maintenance, 24/7 technical support, and proactive system health monitoring; and integrated digital capabilities providing connected offerings, streamlining performance for hospitals with program-enhancing insights. The company sells its products through direct sales organizations, such as capital and clinical sales teams. It has a collaboration agreement with FluoGuide A/S for head & neck cancer. The company was incorporated in 1995 and is headquartered in Sunnyvale, California.